FREE patent keyword monitoring and additional FREE benefits. http://images1.freshpatents.com/images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents

Cancer Cell

Cancer Cell patent applications listed include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.

Related Categories:

Drug, Bio-affecting And Body Treating Compositions


Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material > Binds Eukaryotic Cell Or Component Thereof Or Substance Produced By Said Eukaryotic Cell (e.g., Honey, Etc.) > Cancer Cell



Anti-cxadr antibody
05/21/15 - 20150140018 - An object is to find a target molecule effective for cancer treatments and the like and to provide an antibody capable of specifically binding to the molecule, an anticancer agent comprising the antibody as an active ingredient, and so forth. Hence, prostate cancer cell lines (LNCaP-CR cells and LNCaP cells)...

Method of generating human monoclonal antibodies
05/14/15 - 20150132322 - This invention provides a human antibody, a hybridoma cell line for the production of the antibody, a reconstituted mouse strain for the production of the hybridoma, and methods of producing and using thereof....

Methods and compositions for the treatment of cancer and infectious disease using alpha(2) macroglobulin-antigenic molecule complexes
04/30/15 - 20150118253 - The present invention relates to the use of alpha (2) macroglobulin complexes isolated from the serum of a mammal. The invention also relates to methods for making such complexes and compositions comprising alpha (2) macroglobulin complexes, isolated from the serum of a mammal, wherein such compositions are used in methods...

Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
04/30/15 - 20150118254 - The invention relates generally to variant activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these variant anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and...

B cell surface reactive antibodies
03/26/15 - 20150086575 - The invention relates to antibodies that are reactive to the cell surface of CD19+ B cells, including B-cell chronic lymphocytic leukemia (B-CLL) cells, and compositions and methods for using such antibodies, including in the diagnosis and treatment of disorders associated with CD19+ B cells, such as B-CLL....

Mena and alpha5 integrin interaction
03/19/15 - 20150079113 - Methods are provided for treating invasion of a tumor or metastasis of a tumor in a subject comprising administering to the subject an agent which inhibits the interaction of Mena with an alpha5 integrin. Assays for identifying agents that inhibit interaction of Mena with an alpha5 integrin are also provided....

Methods of identifying gene isoforms for anti-cancer treatments
03/12/15 - 20150071947 - Novel methods of classifying subjects as candidates for treatment with agent that inhibits or kills cancer associated mesenchymal cells, tumor initiating cancer cells, or cancer stem cells treatment and subsequent administration of the agent that inhibits or kills cancer associated mesenchymal cells, tumor initiating cancer cells, or cancer stem cells...

Anticancer agent
03/05/15 - 20150064203 - According to the present invention, an anticancer agent is provided that has as an active ingredient thereof a human antibody light chain that demonstrates cytotoxicity against cancer cells and particularly lung cancer cells. The anticancer agent of the present invention primarily comprises: a human antibody κ-type light chain in the...

Gitr antigen binding proteins
03/05/15 - 20150064204 - Antigen binding proteins that activate GITR are provided. Nucleic acids encoding the antigen binding proteins and vectors and cells containing such nucleic acids are also provided. The antigen binding proteins have value in therapeutic methods in which it is useful to to stimulate GITR signaling, thereby inducing or enhancing an...

Methods for diagnosing and treating neuroendocrine cancer
02/19/15 - 20150050294 - The present invention relates to a method for diagnosing neuroendocrine cancers via detecting the presence of N-methyl D-asparate-associated (NMDA) glutamate receptors type 1 and/or type 2. Methods for preventing and treating neuroendocrine cancers are also disclosed....

Markers for the responsiveness to anti-cd44 antibodies
02/12/15 - 20150044232 - The present invention relates to means and methods of determining whether a tumor cell or a cancer cell is responsive to an anti-CD44 antibody or to an antigen binding fragment thereof. The method comprises the determination of the major CD44 isoform in a sample, wherein if the major CD44 isoform...

Ganglioside gd2 as a marker and target on cancer stem cells
02/12/15 - 20150044233 - Methods for determining the presence of cancer stem cells by detecting GD2 expression. Also provided are methods for reducing proliferation of cancer stem cells by contacting the cells with a GD2 targeting agent, such as an anti-GD2 antibody or a GD3 synthase inhibitor. GD3 synthase inhibitor compounds are also provided....

Menainv and cancer invasion and metastasis
02/12/15 - 20150044234 - Methods and compositions are provided for diagnosing or inhibiting invasion or metastasis of a cancer in a subject based on MenaINV....

Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
02/05/15 - 20150037355 - The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that...

Anti-siglec-15 antibodies and uses thereof
02/05/15 - 20150037356 - This disclosure relates to anti-Siglec-15 antibodies and uses thereof, in particular in the treatment of leukaemia, such as acute myeloid leukaemia....

Immune stimulation/metabolic inhibition as antitumor therapy
02/05/15 - 20150037357 - Methods, compositions and compounds that include a nucleic acid comprising a sequence consisting essentially of polyT/polyU and an agent that inhibits the production or activity of an immunosuppressive compound for treating tumors are described....

Composition and methods for treating cancer
02/05/15 - 20150037358 - Compositions and methods for detecting, prognosing, inhibiting, treating, and/or preventing cancer are provided....

Biomarkers for cancer stem cells and related methods of use
01/29/15 - 20150030615 - Novel methods of classifying subjects as candidates for treatment with a cancer associated mesenchymal cell, tumor initiating cancer cell, or cancer stem cell inhibitor treatment and subsequent administration of the cancer associated mesenchymal cell, tumor initiating cancer cell, or cancer stem cell inhibitor are disclosed within....

Modulation of tim receptor activity in combination with cytoreductive therapy
01/22/15 - 20150023986 - A genetic locus and corresponding family of proteins associated with regulation of immune function and cell survival are provided. These genes encode cell surface molecules with conserved IgV and mucin domains. The locus comprising the TIM family is genetically associated with immune dysfunction, including asthma. Furthermore, the TIM gene family...

Use of pdgfr-alpha as diagnostic marker for papillary thyroid cancer
01/08/15 - 20150010582 - Provided herein are methods for identifying a subject with an increased likelihood of developing or having metastatic papillary thyroid cancer (PTC), or a subject with an increased likelihood of developing or having recurrent PTC, and the treatment of such a subject....

Ex vivo nk cell differentiation from cd34+ hematopoietic cells
01/08/15 - 20150010583 - The present invention relates to the ex vivo differentiation of NK cells from CD34+ hematopoietic stem cells. Such NK cells and their progenitor cells can be used in therapies of a broad range of malignancies. In the present invention it is shown that IL-12 modulates ex vivo NK cell differentiation....

Humanized anti-cd134 (ox40) antibodies and uses thereof
12/25/14 - 20140377284 - The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human...

Treatment regimens using multiple pharmaceutical agents
12/25/14 - 20140377285 - The present invention provides for methods and pharmaceutical compositions for treating disorders using treatment regimens involving multiple agents. In one aspect, a method of treatment is provided resulting in reduced toxicity and/or synergistic effect by administration according to a described dosing schedule....

Detection and treatment of cd30+ cancers
12/25/14 - 20140377286 - The application provides methods of diagnosis, prognosis, prophylaxis and treatment of CD30+ cancers....

Cdcp1 and breast cancer
12/11/14 - 20140363448 - The present invention relates to a method for treating breast cancer in a subject having a hyperactivation of the Epidermal Growth Factor Receptor 1 and/or 2 (EGFR and/or ErbB2 HER2), as compared to the normal subject population, or expressing deltaHER2, which method comprises the step of administering to said subject...

Methods, assays, and systems relating to sakt
12/11/14 - 20140363449 - The technology described herein is directed to methods, assays, and systems relating to determining the level of SAKT signaling activity in a sample obtained from a subject as well as methods relating to administering inhibitors and/or agonists of SAKT signaling....

Soluble cd27 (scd27) and the use thereof
11/20/14 - 20140341931 - Disclosed are methods of diagnosing a subject as having a solid tumor or a predisposition to developing a solid tumor. The methods include detecting or quantitating the amount of sCD27 in a serum sample obtained from a subject and comparing that amount of sCD27 with a control value indicative of...

Methods and pharmaceutical compositions for treating cancer
11/13/14 - 20140335106 - A method of treating cancer by inhibiting expression of ubiquitin associated and SH3 domain containing B (UBASH3B) gene or by inhibiting the activity of UBASH3B protein or a functional variant thereof....

Materials and methods for the prevention and treatment of cancer
10/30/14 - 20140322242 - Methods of treating or preventing cancer, or ameliorating a symptom thereof, by administering a muscarinic receptor inhibitor to inhibit cancer metastasis and/or a β adrenergic receptor inhibitor to inhibit tumor initiation are provided. Also provided are pharmaceutical compositions for treating or preventing cancer comprising a muscarinic receptor inhibitor and/or a...

Methods of detecting breast cancer brain metastasis with genomic and epigenomic biomarkers
10/30/14 - 20140322243 - The present invention provides a method of diagnosing a breast cancer central nervous system (CNS) metastasis in a subject, comprising determining the expression level of at least one biomarker in a subject-derived brain or breast tissue comparing the subject-derived expression level with a normal control level obtained from normal brain...

Mic-binding antibodies and methods of use thereof
10/30/14 - 20140322244 - The technology described herein relates to antibodies and/or polypeptides which bind to MIC and inhibit MIC shedding. Methods of using such antibodies and/or polypeptides for the treatment of cancer are also described herein....

Srm/mrm assay for the insulin receptor protein
10/30/14 - 20140322245 - Specific peptides, and derived ionization characteristics of the peptides, from the Insulin Receptor protein (IR), and its isoforms IR-A and IR-B, that are particularly advantageous for quantifying the IR protein, IR-A isoform and/or IR-B isoform, directly in biological samples that have been fixed in formalin by the method of Selected...

Ige anti-hmw-maa antibody
10/30/14 - 20140322246 - In one aspect, there is provided an antibody or a functional fragment thereof, wherein the antibody or functional fragment thereof is capable of binding specifically to high molecular weight melanoma associated antigen (HMW-MAA), and binding to an Fcε receptor....

Method for the diagnosis, prognosis and treatment of cancer metastasis
10/23/14 - 20140314792 - This study describes a method to determine the likelihood of the development of metastasis in a subject suffering from cancer, in addition to a method to design a customized therapy in a subject suffering from cancer, in particular breast, colon, lung, kidney and thyroid cancer, based on the determination of...

Biological materials and uses thereof
10/23/14 - 20140314793 - The invention provides binding molecules, including antibody molecules which selectively bind to a cell surface antigen of a target cell, and wherein the binding molecules, on binding the cell surface antigen, induce cell death of the target cell. There is also provided methods of and pharmaceutical compositions for cell death...

Combination immunotherapy for the treatment of cancer
10/16/14 - 20140308299 - Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors....

Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8
10/16/14 - 20140308300 - The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8....

Cd44 monoclonal antibody for the treatment of b-cell chronic lymphocytic leukemia and other hematological malignancies
10/16/14 - 20140308301 - Compositions including an antibody specific for CD44 are provided. These antibodies specifically bind to hematologic malignant cells. Methods to use the CD44 antibodies to target cells expressing CD44 for therapeutic and diagnostic purposes are also provided....

Methods of modulating the negative chemotaxis of immune cells
10/02/14 - 20140294862 - The current invention is directed to methods of inducing migration of an immune cell toward a cancer cell comprising inhibiting the activity of a chemorepellant released from the cancer cell....

Methods for the treatment and the prognostic assessment of malignant pleural mesothelioma
09/25/14 - 20140286967 - The present invention relates to methods for the treatment and the prognostic assessment of malignant pleural mesothelioma....

Therapeutic and diagnostic methods for manipulating phagocytosis through calreticulin and low density lipoprotein-related receptor
09/18/14 - 20140271683 - Therapeutic and diagnostic methods are provided, which methods relate to the expression of calreticulin on cancer cells and hematopoietic cells....

Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
09/18/14 - 20140271684 - The present invention relates to a method of enhancing the anti-tumor response in a mammal. More particularly, the invention is concerned with combinations comprising a cytokine-secreting cell and an anti-PD-1 antibody, and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer....

Internalizing human monoclonal antibodies targeting prostate and other cancer cells
09/18/14 - 20140271685 - In various embodiments various cancer specific antibodies and immunoconjugates are provided. In certain embodiments the antibodies specifically bind and are internalized into a prostate cancer cell, where the antibodies specifically binds cells that express or overexpress a CD46, and where the antibodies specifically bind sushi domain 1 of said CD46...

Methods and reagents for detection and treatment of esophageal metaplasia
09/11/14 - 20140255430 - The invention described herein relates to the treatment, detection, and diagnosis of various cancers, including esophageal or gastric adenocarcinoma and related metaplasias. The invention also includes a clonal population of Barrett's esophagus progenitor cells and methods of using them for the treatment, detection, and diagnosis of Barrett's esophagus....

Markers of acute myeloid leukemia stem cells
09/11/14 - 20140255431 - Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets....

Silvestrol, silvestrol analogs and uses thereof
09/11/14 - 20140255432 - Disclosed herein are treatment methods, vaccination methods, compositions, co-therapeutic methods, combination therapeutic compositions and kits comprising silvestrol and silvestrol analogs alone or in combination with therapeutic and preventative therapies. Disclosed herein are also methods, compositions and kits that can be used to treat cancer, viral infections, to modulate the immune...

Inhibition of cancer metastasis
09/04/14 - 20140248290 - P-Selectin on platelets and endothelium binds cell surface chondroitin sulfate (CS) proteoglycans, which are abundantly and stably expressed on the surface many cancer cells. Binding of the cancer cells through the CS moieties may be blocked to inhibit the interaction of cancer cells with platelets and endothelium. The present inventors...

Modulation of cellular migration
09/04/14 - 20140248291 - Methods, kits, and compositions are provided for addressing cancer through the interaction of bradykinin (BK) and the bradykinin-2-receptor (B2R). This interaction controls cellular invasion, as has been unexpectedly observed in glioma cells, A composition is provided for the treatment of cancer by disrupting this interaction using an inhibitor or BK...

Compositions and methods for treating cancer
09/04/14 - 20140248292 - The present invention relates to compositions and methods for treating cancer. In particular, the present invention relates to EpCAM-targeted immunotoxins and uses thereof in treating peritoneal cancers expressing EpCAM (e.g., colorectal, ovarian, and pancreatic cancer)....

Novel risk biomarkers for lung cancer
09/04/14 - 20140248293 - Methods and kits for determining a risk of a subject, or subjects for developing lung cancer is disclosed. The method comprises determining a level of catalytic activity of N-methylpurine DNA glycosylase (MPG), or apurinic/apyrimidinic endonuclease 1 (APE1), or both, or MPG and 8-oxoguanine DNA glycosylase (OGG1), or MPG and APE1...

Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases
09/04/14 - 20140248294 - Provided are novel methods and compositions for the diagnosis, prognosis and treatment of gynecological tumors, in particular uterine leiomyoma (UL). Furthermore, novel methods and compositions for the treatment of diseases characterized by an aberrant growth of mesenchymal stem cells and their descendants and for the treatment of pituitary and prostate...

Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
08/28/14 - 20140242095 - The invention relates to modulating the SIRPα—CD47 interaction in order to treat hematological cancer and compounds therefor. In particular, there is also provided SIRPα antibodies and antibody fragments, preferably used for treating hematological cancer....

Gene signature for predicting prognosis of patients with solid tumors
08/07/14 - 20140220043 - Disclosed herein is a driver gene signature for predicting survival in patients with solid tumors, such as hepatocellular carcinoma (HCC) and breast cancer. The gene signature includes ten tumor-associated genes, SH2D4A, CCDC25, ELP3, DLC1, PROSC, SORBS3, HNRPD, PAQR3, PHF17 and DCK. A decrease in DNA copy number or mRNA expression...

Anti-epha2 antibody
07/31/14 - 20140212439 - The present invention provides an antibody which recognizes an epitope recognized by an antibody produced by a hybridoma SH348-1 (FERM BP-10836) or a hybridoma SH357-1 (FERM BP-10837), an antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, an antibody obtained by humanizing the antibody produced by the hybridoma SH348-1...

Protein involved in detection of cancer metastasis and a treatment thereof
07/17/14 - 20140199330 - Using phosphoproteomics, we profiled the phosphorylation levels of hundreds of proteins concurrently across an isogenic model of breast cancer metastasis. Among them is TRPV4, a calcium channel that we found to be overexpressed in invasive breast tumors compared to ductal carcinoma in situ, a pre-neoplastic lesion and normal tissues. TRPV4...

Anti-hdlk-1 antibody having an antitumor activity in vivo
07/10/14 - 20140193432 - The present invention provides: antibodies specifically reacting against hDlk-1 and having anti-tumor activity in vivo (anti-hDlk-1 antibodies, and in particular, humanized anti-hDlk-1 antibodies); fragments of the antibodies; hybridomas that produce the antibodies; a complex of the antibody or antibody fragment and an agent; a pharmaceutical composition, a tumor therapeutic agent,...

Bcma-based stratification and therapy for multiple myeloma patients
07/10/14 - 20140193433 - The present invention relates to methods for the stratification of a multiple myeloma (MM) patient comprising determining whether or not B-cells, preferably malignant B-cells of said patient express BCMA protein on their surface. Also, methods for selecting an antibody-based multiple myeloma (MM) therapy is based on whether or not BCMA...

Pharmaceutical composition for treatment and/or prophylaxis of cancer
07/10/14 - 20140193434 - It is intended to identify a cancer antigenic protein specifically expressed on the surface of cancer cells and to provide an antibody targeting the antigenic protein and use of the antibody as a therapeutic and/or preventive agent for cancer. The present invention provides an antibody or a fragment thereof which...

Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists
07/03/14 - 20140186374 - We demonstrate herein that neuritin controls the homeostasis of regulatory T cells in an antigen dependent manner. Based on this discovery, we describe herein the application of neuritin as a therapeutic agent to manipulate antigen specific regulatory T cells in various disease settings is described. Thus manipulation of Treg cells...

Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
07/03/14 - 20140186375 - Pharmaceutical compositions comprising a nucleic acid, a gene delivery polymer, and at least one adjunctive chemotherapeutic drug for the treatment of mammalian cancer or hyperproliferative disorders and methods of using thereof for the treatment of mammalian cancer or hyperproliferative disorders by intratumoral, intraperitoneal or systemic injection....

Compositions and methods for inhibiting ccl3
07/03/14 - 20140186376 - The present invention relates to the discovery that CCL3, through at least one of its receptors CCR1 and CCR5, plays a role in the pathologies associated with myeloid neoplasms. In various embodiments, the pathologies associated with myeloid neoplasms treatable by the compositions and methods of the invention described herein include,...

Sema5b peptides and vaccines including the same
06/26/14 - 20140178409 - As discussed in detail herein, isolated epitope peptides derived from SEMA5B bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above mentioned amino acid sequences and...

Methods of treating acute myeloid leukemia by blocking cd47
06/12/14 - 20140161825 - Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc....

Non-self t-cell epitope fused to an antibody that recognises a tumour-specific cell-surface receptor and uses thereof
06/12/14 - 20140161826 - A first composition comprising a ligand part being able to specifically bind to a target, the target being on a diseased cell of an organism, and an epitope part having a non-self epitope, or encoding a non-self epitope, the non-self epitope not naturally being encoded by the organism, wherein the...

Alpha5-beta1 antibodies and their uses
06/05/14 - 20140154268 - The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin α5β1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided....

Targeted nanovectors and their use for treatment of brain tumors
06/05/14 - 20140154269 - In some embodiments, the invention pertains to therapeutic compositions for treating a brain tumor. Such therapeutic compositions generally comprise: (1) a nanovector; (2) an active agent associated with the nanovector with activity against brain tumor cells; and (3) a targeting agent associated with the nanovector with recognition activity for a...

Anti-mesothelin antibodies
05/08/14 - 20140127237 - This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and become internalized by mesothelin-positive cells and also induce an immune effector activity such as antibody dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to mesothelin expressing cells as well...

Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
05/08/14 - 20140127238 - The invention provides methods for treating patients which methods comprise methods for predicting responses of cells, such as tumor cells, to treatment with therapeutic agents. These methods involve measuring, in a sample of the cells, levels of one or more components of a cellular network and then computing a Network...

Treatment of cancer using smad3 inhibitor
05/01/14 - 20140120116 - The present invention resides in the discovery that Smad3, a key downstream mediator of TGF-β signaling, plays a critical role in development and progression of cancer. Thus, this application provides for a novel method of treating cancer by inhibiting Smad3 signaling, such as through administration of SIS3, an inhibitor of...

Treatment of tumors using specific anti-l1 antibody
05/01/14 - 20140120117 - The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment....

Human c-fms antigen binding proteins
04/17/14 - 20140105916 - Antigen binding proteins that bind to human c-fms protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of c-fms to CSF-1, reduce monocyte migration into tumors, and reduce the accumulation of tumor-associated macrophages....

Frizzled-binding agents and uses thereof
04/17/14 - 20140105917 - Novel anti-cancer agents, including, but not limited to, antibodies and other polypeptides, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using...

Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
04/17/14 - 20140105918 - The present invention relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in prostate...

Synergistic inhibition of erbb2/erbb3 signal pathways in the treatment of cancer
04/17/14 - 20140105919 - Methods for treating tumors comprising cells overexpressing ErbB2 or ErbB3 are provided, and comprise inhibiting the biologic activity of one or more of ErbB2 and ErbB3 in the cells and inhibiting the expression or the biologic activity of a constituent of a signal pathway connected with ErbB2 or ErbB3 signaling....